ClinicalTrials.gg
CompletedNCT04428255Updated Apr 28, 2026

A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP

A Phase 2/3 interventional study of HBM9161 Dose A and HBM9161 Dose B in Primary Immune Thrombocytopenic Purpura, sponsored by Harbour BioMed (Guangzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Harbour BioMed (Guangzhou) Co. Ltd. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China — 82 open to participants now, 92 under way, 12 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · China.

Enrollment
113th of 167
36 · median 62
Started
2020
with 12 others
Phase 2/3
4 of 185
2 open now
Registered
60th of 185
by date

Among the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, this one is the 113th largest by enrollment of the 167 interventional ones that give a count, is one of 13 that started in 2020, is one of 4 in phase 2/3, and was the 60th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

82 of the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, or all of them as a file.
02

Study summary

To select a dose and to make a decision for Phase 3 study

Read the detailed description

The onset of primary immune thrombocytopenia is thought to be increased platelet destruction and decreased platelet production due to anti-platelet antibodies. HBM9161 is a fully human anti-FcRn monoclonal antibody that can effectively remove pathogenic IgG, thereby relieving platelet destruction and rapidly increasing platelet counts in patients. The study will be conducted in a Phase 2/3 operational seamless design, with group Dose A and Dose B of HBM9161 and a placebo group in Phase 2.

03

Conditions studied

  • Primary Immune Thrombocytopenic Purpura

Keywords

  • ITP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age at the screening visit, male or female.
  2. Persistent or chronic ITP whose average number of at the screening visit and pre-dose (at least 1 day apart) is \< 30 × 10\^9/L, and not > 35 × 10\^9/L for any of two tests. No severe bleeding within 4 weeks prior to the screening visit.
  3. Patients who have received and failed at least 1 of ITP therapy ( and/or intravenous gamma globulin), or who are , intolerable, or refuse standard therapy.
  4. Patients will be allowed to use a stable dose of concomitant drugs for the treatment of ITP. e.g., glucocorticoid, danazol, (azathioprine, cyclosporine A, mycophenolate mofetil) and eltrombopag.

Exclusion criteria

Exclusion Criteria:

  1. Other systemic diseases other than ITP.
  2. Multi-lineage immune cytopenias, such as Evan's syndrome, autoimmune pancytopenia.
  3. Secondary ITP.
  4. Received a vaccine within 4 weeks prior to the first dose of the study drug or planned during the study.
  5. Use of anticoagulants or any agents that have antiplatelet effect or can affect thrombopoiesis within 3 weeks prior to the first dose of the study drug.
  6. Received blood transfusion within 1 week prior to the first dose of the study drug.
  7. Received the intravenous gamma globulin, anti-D immunoglobulin, or plasmapheresis within 2 weeks prior to the first dose of the study drug.
  8. Received high-dose dexamethasone or high-dose methylprednisolone within 2 weeks prior to the first dose of the study drug.
  9. Received recombinant human thrombopoietin (rhTPO) within 4 weeks prior to the first does of the study drug.
  10. Received rituximab or other non-rituximab anti-CD20 drugs within 6 months prior to the first does of the study drug.
  11. Treated with splenectomy within 4 weeks prior to first dose of the study drug.
  12. Any thromboembolic or embolic events within 12 months prior to the first does of the study drug.
  13. Serum total IgG \< 700 mg/dL at the screening visit.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    HBM9161 Dose A

    Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo

    Drug: HBM9161 Dose A

  • Experimental
    HBM9161 Dose B

    Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo

    Drug: HBM9161 Dose B

  • Placebo comparator
    Placebo

    Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo

    Drug: Placebo

Interventions

  • HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly

  • HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly

  • DrugPlacebo

    HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly

06

What researchers measure

Primary outcomes

  1. Proportion of patients who achieve the early response.

    The primary endpoint of phase 2

    Time frame: 7 weeks

Secondary outcomes

  1. Proportion of patients who achieve platelet count ≥ 50 × 10^9/L at least 2 times within 7 weeks.

    Time frame: 7 weeks

07

Study locations

1 site
  • Hematology hospital, Chinese academy of medical sciences
    Tianjin, Tianjin Municipality 300020, China
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Aug 2021, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2020
First posted
Jun 11, 2020
StartActual
Jul 24, 2020
Primary completionActual
Aug 10, 2021
CompletionActual
Aug 11, 2021
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04428255
Lead sponsor
Harbour BioMed (Guangzhou) Co. Ltd.
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Jul 24, 2020
Primary completion
Aug 10, 2021
Completion
Aug 11, 2021
Last update
Apr 28, 2026

Study contacts

Renchi Yang
principal investigator · Hematology hospital, Chinese academy of medical sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBM9161

Start the discussion